Filings monitor · VTRS

What Viatris Inc's SEC filings said

10-Q for 2026Q3, filed 5 Nov 2026, and 1 8-K since. Each line is something a filing stated, ranked by score and linked to its source.

Ranked highest

1. Guidance withdrawn90 · rule score among filings · 8-K Item 2.02 · 5 Nov 2026
   Also, consistent with our disciplined and balanced capital allocation strategy, we continued returning additional value to shareholders in the quarter and expect the Pacira transaction to have minimal impact on our gross leverage ratio…
2. Guidance / Outlook75 · importance in its document · 8-K exhibit · 5 Nov 2026
   On November 5, 2026, Viatris raised its 2026 guidance midpoints for total revenues to $14.8 billion, adjusted EBITDA to $4.5 billion, adjusted EPS to $2.60, and free cash flow excluding transaction-related and restructuring-related costs…
3. Acquisition / Partnership / Divestiture65 · importance in its document · 8-K exhibit · 5 Nov 2026
   Viatris agreed to acquire all outstanding common shares of Pacira BioSciences for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. The transaction was expected to close by the end of November 2026.…
4. Other Income (Expense), Net63 · importance in its document · 10-Q · 2026Q3
   Other expense, net fell by $481.6 million to $18.3 million for the nine months ended September 30, 2026, from $499.9 million in the prior-year period. The primary driver was the absence of the prior-year $499.8 million loss from…
5. Income Tax Rate Changes57 · importance in its document · 10-Q · 2026Q3
   For the nine months ended September 30, 2026, Viatris recorded an $84.3 million income tax provision, compared with a $147.2 million benefit in the prior-year period, a $231.5 million change. The current-period provision reflected losses…

Ranked by score, 0–100. A topic read from a document carries its importance within that document; an 8-K event carries the rule score that ranks a filing among filings. Neither is about the share price, and the two scales are named on each row because they are not the same measure.

Latest report: 10-Q · 2026Q3 filed 5 Nov 2026

Full report · Filing on EDGAR

• Other Income (Expense), NetImportance 63
  Other expense, net fell by $481.6 million to $18.3 million for the nine months ended September 30, 2026, from $499.9 million in the prior-year period. The primary driver was the absence of the prior-year $499.8 million…
• Acquisition / Partnership / DivestitureImportance 59 · +1 more on this subject
  On October 8, 2026, Viatris agreed to acquire all outstanding Pacira shares for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. The company commenced its offer on October 30, which is…
• Income Tax Rate ChangesImportance 57
  For the nine months ended September 30, 2026, Viatris recorded an $84.3 million income tax provision, compared with a $147.2 million benefit in the prior-year period, a $231.5 million change. The current-period…
• Revenue Concentration RiskImportance 55
  Viatris’ ten largest products represented approximately 41% of net sales in the third quarter of 2026, compared with 38% in the third quarter of 2025. For the first nine months, the top ten represented approximately…
• Capital Expenditure PlanImportance 54
  Viatris reported capital expenditures of approximately $178.4 million for the nine months ended September 30, 2026, primarily for equipment and facilities. For calendar 2026, the company expects capital expenditures of…
• Capital Return ProgramImportance 51
  Viatris’ board-authorized share repurchase program permits repurchases of up to $2.0 billion and has no expiration date. In the third quarter of 2026, the company repurchased approximately 8.9 million shares for $150.0…
• Nashik Supply DisruptionImportance 46
  A February 2026 fire at Viatris’ Nashik, India oral solid dose facility temporarily suspended manufacturing, and subsequent FDA inspection observations led to remediation and further operational disruption.…
• Headcount / RestructuringImportance 46 · +1 more on this subject
  Viatris began implementing restructuring activities following its enterprise-wide strategic review, announced February 26, 2026, to optimize commercial capabilities, enabling functions, R&D, medical affairs, regulatory…
• Liquidity and Debt PositionImportance 44
  Viatris held $1.79 billion of cash and cash equivalents at September 30, 2026. The company had access to a $3.5 billion revolving facility maturing in September 2029 and a receivables facility of up to $600 million…
• Accrued Legal and RegulatoryImportance 38
  Viatris reported approximately $459 million accrued for legal contingencies as of September 30, 2026, and said it faces disputes, governmental or regulatory inquiries, investigations, proceedings, and litigation in the…
• Supply Chain AgreementsImportance 38
  Viatris continues to manufacture and supply products for buyers under agreements associated with its divestitures, generally for periods of one to 10 years depending on the geographic market and products involved. Some…
• Operating Cash Flow TrendsImportance 35
  Net cash provided by operating activities increased $169.4 million, or approximately 11%, to $1.67 billion for the nine months ended September 30, 2026, from $1.50 billion in the prior-year period. Viatris attributed…

8-K filings last 12 months

• Guidance withdrawn5 Nov 2026 · 8-K Item 2.02 · Flagged · rule score 90
  “Also, consistent with our disciplined and balanced capital allocation strategy, we continued returning additional value to shareholders in the quarter and expect the Pacira transaction to have minimal impact on our gross leverage ratio…”
  Read from the attached exhibit: Guidance / Outlook · Acquisition / Partnership / Divestiture · Net Income and Profitability
• Press release attached to an 8-K8 Oct 2026 · 8-K
  Read from the attached exhibit: Acquisition / Partnership / Divestiture · Non-Opioid Pain Market Positioning · Pain Pipeline Development
• Results (release not read)6 Aug 2026 · 8-K Item 2.02 · Routine · rule score 20
  Read from the attached exhibit: Guidance and Outlook · Free Cash Flow and Liquidity · Acquisition / Partnership / Divestiture
• New debt1 Jul 2026 · 8-K Items 1.01, 2.03 · Routine · rule score 25
• New debt18 Jun 2026 · 8-K Items 1.01, 2.03 · Routine · rule score 25
• Results (release not read)7 May 2026 · 8-K Item 2.02 · Routine · rule score 20
• Executive pay change4 May 2026 · 8-K Item 5.02 · Routine · rule score 5
  “Ms. Mistras’ resignation was not related to any disagreement between Ms. Mistras and the Company on any matter relating to the Company’s accounting practices, financial statements, internal controls, or operations.”
• Restructuring, first in three years · Results (release not read)26 Feb 2026 · 8-K Items 2.02, 2.05 · Flagged · rule score 65
• Management change (filing not read)3 Feb 2026 · 8-K Item 5.02 · Routine · rule score 20

Earlier reports

• 10-Q · 2026Q2filed 6 Aug 2026
  Other Income (Expense), Net · Acquisition / Partnership / Divestiture · Income Tax Rate Changes

Topics are read from the text of the 10-K, 10-Q or the exhibit attached to an 8-K, each linked to the passage it came from. 8-K events are labelled by fixed rules from the item codes and the filing text — the same rules for every company and every year. The Full Picture merges these with earnings calls and news.